Molekylærbiologiske undersøkelser av brystkreftsvulster og maligne melanomer for identifikasjon av genforandringer som gir behandlingsresistens samt utvikling av metastaser.
- Prosjektnummer
- 911007
- Ansvarlig person
- Per Eystein Lønning
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Additive endocrine therapy for advanced breast cancer - back to the future.
Acta Oncol 2009;48(8):1092-101.
PMID: 19863216
Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.
Eur J Pharmacol 2009 Dec;625(1-3):6-22. Epub 2009 okt 18
PMID: 19836383
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
Br J Cancer 2009 Oct;101(8):1253-60. Epub 2009 sep 15
PMID: 19755984
Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.
J Steroid Biochem Mol Biol 2009 Oct;117(1-3):31-41. Epub 2009 jul 8
PMID: 19591931
Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.
Cancer Res 2009 Jul;69(13):5331-9. Epub 2009 jun 9
PMID: 19509230
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.
Clin Cancer Res 2009 Jun;15(12):4165-73. Epub 2009 jun 9
PMID: 19509150
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
Eur J Cancer 2009 Mar;45(4):527-35. Epub 2008 des 4
PMID: 19062270
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.
Breast Cancer Res 2008;10 Suppl 4():S22. Epub 2008 des 18
PMID: 19128436
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Clin Cancer Res 2008 Oct;14(19):6330-5.
PMID: 18829517
Aromatase inhibition versus placebo.
Clin Breast Cancer 2008 Aug;8(4):374.
PMID: 18757268
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
PLoS ONE 2008;3(8):e3062. Epub 2008 aug 26
PMID: 18725978
Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
J Clin Oncol 2008 Oct;26(30):4859-61. Epub 2008 aug 25
PMID: 18725646
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
Oncologist 2008 Aug;13(8):829-37. Epub 2008 aug 11
PMID: 18695261
GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
Cancer Res 2008 Jul;68(14):5562-71.
PMID: 18632608
Experience with exemestane in the treatment of early and advanced breast cancer.
Expert Opin Drug Metab Toxicol 2008 Jul;4(7):987-97.
PMID: 18624685
Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?
Anticancer Drugs 2008 Mar;19 Suppl 2():S11-3.
PMID: 18337640
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
Int J Cancer 2008 Aug;123(3):577-85.
PMID: 18498133
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.
Oncogene 2008 Sep;27(39):5182-94. Epub 2008 mai 12
PMID: 18469852
Indications and limitations of third-generation aromatase inhibitors.
Expert Opin Investig Drugs 2008 May;17(5):723-39.
PMID: 18447598
An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
J Steroid Biochem Mol Biol 2008 Mar;109(1-2):90-5. Epub 2007 des 15
PMID: 18242079
Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression.
J Steroid Biochem Mol Biol 2008 Feb;108(3-5):196-202. Epub 2007 sep 14
PMID: 17996443
Breast cancer prognostication and prediction: are we making progress?
Ann Oncol 2007 Sep;18 Suppl 8():viii3-7.
PMID: 17890212
Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres.
Nucleic Acids Res 2007;35(21):7267-78. Epub 2007 okt 24
PMID: 17959650
Aromatase inhibitors--socioeconomical issues.
J Steroid Biochem Mol Biol 2007 Aug-Sep;106(1-5):55-61. Epub 2007 mai 24
PMID: 17604616
Adjuvant endocrine treatment of early breast cancer.
Hematol Oncol Clin North Am 2007 Apr;21(2):223-38.
PMID: 17512446
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Acta Oncol 2007;46(2):199-203.
PMID: 17453369
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
Acta Oncol 2007;46(2):153-64.
PMID: 17453363
Mutations and polymorphisms of the p21B transcript in breast cancer.
Int J Cancer 2007 Aug;121(4):908-10.
PMID: 17443496
Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
J Steroid Biochem Mol Biol 2007 Apr;104(1-2):27-34. Epub 2007 mar 9
PMID: 17350249
Breast cancer prognostication and prediction in the postgenomic era.
Ann Oncol 2007 Aug;18(8):1293-306. Epub 2007 feb 21
PMID: 17317675
P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.
Int J Cancer 2007 Jun;120(12):2749.
PMID: 17315192
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Lancet 2007 Feb;369(9561):559-70.
PMID: 17307102
ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
Pharmacogenet Genomics 2007 Feb;17(2):127-36.
PMID: 17301692
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clin Cancer Res 2005 Jan;11(2 Pt 2):861s-4s.
PMID: 15701878
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.
Clin Cancer Res 2005 Jan;11(2 Pt 2):878s-83s.
PMID: 15701881
Exemestane for breast cancer prevention: a feasible strategy?
Clin Cancer Res 2005 Jan;11(2 Pt 2):918s-24s.
PMID: 15701887
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin.
Oncol Rep 2005 Mar;13(3):525-30.
PMID: 15706428
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
Eur J Cancer 2005 Mar;41(5):694-701. Epub 2005 jan 21
PMID: 15763644
[Aromatase inhibitors in the therapy for breast cancer]
Tidsskr Nor Laegeforen 2005 Mar;125(6):723-8.
PMID: 15776065
Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts.
Hum Gene Ther 2005 Mar;16(3):381-92.
PMID: 15812233
Aromatase inhibition: translation into a successful therapeutic approach.
Clin Cancer Res 2005 Apr;11(8):2809-21.
PMID: 15837728
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Acta Oncol 2005;44(1):23-31.
PMID: 15848903
Aromatase inhibitors--socio-economical issues.
J Steroid Biochem Mol Biol 2005 May;95(1-5):137-42.
PMID: 15955693
Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations.
J Steroid Biochem Mol Biol 2005 May;95(1-5):75-81.
PMID: 15975785
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
J Clin Oncol 2005 Aug;23(22):5126-37. Epub 2005 jun 27
PMID: 15983390
Genomics-based prognosis and therapeutic prediction in breast cancer.
J Natl Compr Canc Netw 2005 May;3(3):291-300.
PMID: 16002001
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
J Steroid Biochem Mol Biol 2005 May;95(1-5):105-11.
PMID: 16023338
Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
J Steroid Biochem Mol Biol 2005 Sep;96(5):415-22.
PMID: 16168635
Genomics in breast cancer-therapeutic implications.
Nat Clin Pract Oncol 2005 Jan;2(1):26-33.
PMID: 16264853
Oestrogen suppression--lessons from clinical studies.
Best Pract Res Clin Endocrinol Metab 2004 Mar;18(1):33-45.
PMID: 14687596
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med 2004 Mar;350(11):1081-92.
PMID: 15014181
Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.
Trends Mol Med 2004 Mar;10(3):113-8.
PMID: 15102353
Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
Clin Cancer Res 2004 May;10(10):3438-43.
PMID: 15161699
Aromatase inhibitors in breast cancer.
Endocr Relat Cancer 2004 Jun;11(2):179-89.
PMID: 15163297
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
J Natl Cancer Inst 2004 Jun;96(11):884; author reply 884-5.
PMID: 15173277
Cell-type-specific responses to chemotherapeutics in breast cancer.
Cancer Res 2004 Jun;64(12):4218-26.
PMID: 15205334
PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.
Exp Cell Res 2004 Aug;298(1):58-73.
PMID: 15242762
Mutation of GATA3 in human breast tumors.
Oncogene 2004 Oct;23(46):7669-78.
PMID: 15361840
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
Oncogene 2004 Nov;23(52):8535-44.
PMID: 15361853
IGF-1 and breast cancer.
Novartis Found Symp 2004;262():205-12; discussion 212-4, 265-8.
PMID: 15562831
Molecular classes of breast cancer and its clinical relevance.
Curr Breast Cancer Rep 1: 183-189, 2009
Tailored targeted therapy for all; a realistic and worthwhile objective? Breast Cancer res 11(Suppl 23); S7: 1-5, 2009
Breast Cancer Res 11(Suppl 3); S7:1-5, 2009 (skal inn i PubMed)
Hormonal therapies of metastatic breast cancer: the past and the present.
Cancer metastasis - Biology and Treatment 11: Metastasis of breast cancer. Eds. Mansel RE, Fodstad O, Jiang WG. Springer Publishers, Dordrecth, netherlands; 405-423, 2007
Adjuvant treatment: the contribution of expression micro-arrays.
Breast Cancer Res 9 (S2): s14;1-5, 2007
Role of endocrine therapy in breast cancer - where are we going?
Baillieres Best Pract Res; Clin Endocrinol Metab 18:182-195,2004
Understanding chemoresistance - the ultimate challenge in cancer therapy.
Breast Cancer Online (BCO), 7,4,2004
PhD
- Disputert:
- mars 2009
- Hovedveileder:
- Per Eystein Lønning
Chemoresistance in breast cancer: Alterations in the p53 pathway and integrity of the DNA damage response
- Disputert:
- februar 2007
- Hovedveileder:
- Per Eystein Lønning
Germline genetic alterations affecting CDKN2A, MDM2 and CDKN1A in melanoma and breast cancer patients
- Disputert:
- mars 2007
- Hovedveileder:
- Per Eystein Lønning
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest